Vertex EVP sells shares in pre-set trading plan

Vertex Pharmaceuticals executive Mark E. Bunnage reported two stock dispositions.

Rhea-AI Filing Summary

Vertex Pharmaceuticals executive Mark E. Bunnage reported two stock dispositions. On February 25, 2026, he completed an open-market sale of 620 shares of common stock at an average price of $486.35 per share. After this sale, he directly held 7,284 shares.

On February 24, 2026, he disposed of 582 shares at an average price of $485.11 per share to cover tax obligations, rather than as an open-market sale. The transactions were made under a company-approved Rule 10b5-1 trading plan that Dr. Bunnage entered into on November 26, 2025.

Insider Trade Summary

Net Seller: 620 shares

Net Sell 2 txns

Insider Bunnage Mark E.

Role EVP, Chief Scientific Officer

Sold 620 shs ($302K)

Type	Security	Shares	Price	Value
Sale	Common Stock	620	$486.35	$302K
Exercise Price or Tax Liability	Common Stock	582	$485.11	$282K

Holdings After Transaction: Common Stock — 7,284 shares (Direct)

Footnotes (1)

1. F1. Transaction made pursuant to Dr. Bunnage's company approved trading plan under Rule 10b5-1, which was entered into on 11/26/2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did VRTX executive Mark Bunnage report?

Mark E. Bunnage reported two stock dispositions, including an open-market sale and a tax-related share delivery. Together they covered 1,202 Vertex shares and left him holding 7,284 shares directly after the open-market sale.

How many Vertex (VRTX) shares did Mark Bunnage sell in the market?

He sold 620 shares of Vertex common stock in an open-market transaction. The shares were sold at an average price of $486.35 each, and following this trade he directly held 7,284 Vertex shares.

What was the tax-withholding transaction reported by VRTX’s Mark Bunnage?

He disposed of 582 Vertex shares to satisfy tax obligations by delivering stock instead of cash. This tax-withholding disposition occurred at an average price of $485.11 per share, separate from his open-market sale.

Was the VRTX insider sale by Mark Bunnage under a 10b5-1 plan?

Yes, the open-market sale was executed under a company-approved Rule 10b5-1 trading plan. The filing states Dr. Bunnage adopted this pre-arranged plan on November 26, 2025, before the reported February 2026 transactions.

What is Mark Bunnage’s role at Vertex Pharmaceuticals (VRTX)?

Mark E. Bunnage serves as Executive Vice President and Chief Scientific Officer at Vertex. His Form 4 identifies him as an officer of the company, not a director or ten percent beneficial owner.

How many Vertex (VRTX) shares does Mark Bunnage hold after these transactions?

After the open-market sale reported for February 25, 2026, he directly owns 7,284 shares. This figure reflects his remaining common stock holdings following the 620-share sale disclosed in the Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/26/2026 - 06:06 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bunnage Mark E.

(Last) (First) (Middle)

C/O VERTEX PHARMACEUTICALS INCORPORATED

50 NORTHERN AVENUE

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/24/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/24/2026		F		582	D	$485.11	7,904	D
Common Stock	02/25/2026		S(1)		620	D	$486.35	7,284	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to Dr. Bunnage's company approved trading plan under Rule 10b5-1, which was entered into on 11/26/2025.

Remarks:

	/s/ Christiana Stevenson, Attorney-in-Fact	02/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.